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Management of Hypertension in Older People
NAY THU WIN1 AND SHYH POH TEO2
From 1IJN National Heart Institute, Malaysia; 2Department of Internal Medicine, RIPAS Hospital, Brunei Darussalam
WIN and TEO: Management of Hypertension in Older People: Systolic hypertension above >160 mmHg is associated
with cardiac, renal and cerebrovascular complications. In older people, treating hypertension offers cardiovascular
benefits. Reduced salt intake and weight loss for obese older people improves blood pressure without any risk of
adverse drug reactions. Blood pressure reduction is more important than the type of antihypertensive for cardiovascular
risk reduction. The recommended drugs to start an older patient with isolated systolic hypertension are thiazides,
calcium-channel blockers or angiotensin II receptor blocker. Studies were performed on relatively fit older patients,
so benefits may not be generalisable to frail elderly. Alpha-blockers and beta-blockers are not recommended for first
line therapy of hypertension but may be considered if there are other indications for their use. (J HK Coll Cardiol
2017;25:1-8)
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Introduction
Older people are less likely to receive treatment
for hypertension. Hypertension is also more difficult to
control with age, particularly in women.1,2 In United
States, although increasing awareness among patients
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and physicians may have improved treatment
and control between 1988 to 2008, it was still
disproportionately less for those age 60 years and over.3
These high rates of hypertension and inadequate
treatment and control for older people was also found
in low and middle income countries.4
The prevalence of hypertension increases with
age. There is also a step-wise increase in risk of major
cardiovascular events with each hypertension stage. For
patients age 80 years and older, the Framingham Heart
Study found a 9.5% risk with normal blood pressure to
19.8%, 20.3% and 24.7% in pre-hypertension, Stage 1
and Stage 2 hypertension respectively. 1 Therefore,
further study was required to assess whether
hypertension treatment in older people attenuated this
risk.
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The potential benefit of treating hypertension in
older people was identified since the 1980s. Coope and
Warrender found reduced stroke risk when hypertensive
patients between 60 to 79 years old were treated, mostly
with atenolol and bendrofluazide. 5 The European
Working Party on High Blood Pressure in the Elderly
trial (EWPHE) identified reduced cardiac mortality and
a trend towards improved stroke mortality when treating
those above 60 years with hydrochlorothiazide and
triamterene.6
When EWPHE subgroup analysis was performed,
although participants 70 years and older had similar
improved outcomes as those between 60 to 69 years,
there appeared little benefit for patients over 80 years
old.7
The Swedish Trial in Old Patients with
Hypertension (STOP-Hypertension) further extended
the evidence for treatment to 84 years. Participants aged
70 to 84 from primary health care who received
treatment with beta-blockers and diuretics had reduced
stroke, myocardial infarction, cardiovascular death,
stroke mortality and all-cause mortality.8
The Hypertension in Very Elderly Trial (HYVET)
then specifically reviewed people aged 80 years and
older. Treatment with indapamide and perindopril as
required reduced strokes and stroke mortality, cardiac
failure, cardiovascular mortality and all-cause mortality.9
These studies offer cumulative evidence that age
alone is not an appropriate reason to withhold treatment.
Management considerations for treating hypertension
are discussed subsequently based on studies specifically
of older people.

Hypertension Guidelines: The Need To
Individualise Treatment
Table 1 summarises the recommendations from
three major recent guidelines on hypertension treatment
for older people (NICE, ESH/ESC, JNC8).10-12 There
are subtle differences between them, reflecting
uncertainty in some aspects of management. All studies
performed also enrolled ambulatory older people with
isolated systolic hypertension so these recommendations
may not be generalisable to frail older people or those
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with multiple medical conditions.
There is consensus that systolic blood pressure
above 160 mmHg should be treated to a target of
below 150 mmHg.10-12 The Systolic Blood Pressure
Intervention Trial (SPRINT) challenges this as patients
75 years and older had lower rates of major
cardiovascular events and all-cause mortality
with intensive (<120 mmHg) rather than standard
(<140 mmHg) treatment.13 A meta-analysis of studies
on blood pressure targets may help clarify this issue.
Whether benefits of intensive treatment without adverse
events can be replicated outside trial settings with close
supervision is uncertain.
While awaiting a consensus after the SPRINT
trial, the guideline recommendations remain clear.
Treatment is appropriate above systolic blood pressure
of 150/90. The intensive or standard target should be
individualised to tolerability of antihypertensive
treatment and the general health of the patient i.e. fitter,
independent older patients may benefit more from the
intensive approach.
NICE guidelines10 additionally gives targets for
ambulatory or home blood pressure monitoring of
135/85 for under 80 years and 145/85 for above 80
years. For practical purposes, we would advocate for
clinic blood pressure targets, with ambulatory or home
blood pressure monitoring only if there was a concern
regarding white coat hypertension.

Non-pharmacological Therapy: Reduced
Salt Intake and Weight Loss (If Obese)
A small trial of 47 people 60 to 78 years old found
reduced salt intake resulted in blood pressure lowering
for both normotensive and hypertensive subjects, similar
to a thiazide treatment effect. 14 The findings were
replicated in the Trial of Non-pharmacologic
Interventions in the Elderly (TONE). When participants
aged 60 to 80 years old reduced sodium intake or lost
weight (if they were obese), there was improvement in
blood pressure control compared to usual care. However,
there was no reduction in cardiovascular events.15
As reduced salt intake and weight loss for obese
older people improves blood pressure without any risk
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Table 1. Summary of guideline recommendations specific for older patients
NICE 2011
ESH/ESC 2013
When to Treat
Stage 1 hypertension
'Elderly' (not defined)
(SBP 140-159 mmHg or
SBP >= 160 mmHg
DBP 90-99 mmHg) if under
80 years old with one or
more of the following:
Target organ damage,
established cardiovascular
disease, renal disease, diabetes,
10 years cardiovascular
risk of 20% or greater

JNC8 2014
Age 60 years and older:
SBP 150 mmHg or higher
DBP 90 mmHg or higher

Stage 2 hypertension
(SBP 160 mmHg or higher
or DBP 100 mmHg or
higher) at any age
Blood Pressure Goals

Age under 80 years:
Clinic BP below
140/90 mmHg
ABPM or HBPM below
135/85 mmHg during usual
waking hours

SBP between 140
and 150 mmHg

SBP lower than 150 mmHg
DBP lower than 90 mmHg

Age 80 years and over:
Clinic BP below
150/90 mmHg
ABPM or HBPM
below 145/85 mmHg

Age 80 years and over:
SBP between 140 and
150 mmHg provided
'good physical and
mental conditions'

Hypertension
management when
adverse reaction
present e.g.
orthostatic
hypotension or falls

Measure postural blood
pressure and if confirmed,
review medications and
consider referral to
specialist care

SBP goals to be adapted
to individual tolerability
for 'fragile elderly'
Decisions to be made by
'treating physician based
on monitoring of clinical
effects of treatment'

No specific
recommendations

Cardiovascular
Comorbidities

No specific
recommendations

No specific
recommendations

No specific
recommendations

Cerebrovascular
Comorbidities

No specific
recommendations

'Elderly hypertensives
with previous stroke or
TIA, SBP values for
intervention and goal may
be considered to be
somewhat higher'

No specific
recommendations

Age under 80 years:
If fit, can consider
SBP <140 mmHg

(continued on page 3)
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Table 1. Summary of guideline recommendations specific for older patients (cont'd)
NICE 2011
ESH/ESC 2013

JNC8 2014

Renal Comorbidities

No specific
recommendations

No specific
recommendations

Diabetic Comorbidities

No specific
recommendations

Consider HBA1c target
No specific
of 7.5 to 8.0% in 'fragile
recommendations
elderly' patients with a longer
duration of diabetes, more
comorbidities and at high risk
of complications

Non-pharmacological

No specific
recommendations

No specific
recommendations

Pharmacological

Age over 55 years:
Step 1: Calcium channel
blockerIf intolerance from
oedema, evidence of heart
failure or high risk of heart
failure, thiazide diuretic

All antihypertensive agents Initial antihypertensive
are recommended and can
treatment should include
be used in the elderly
thiazide type diuretic,
calcium channel blocker,
'Diuretics and calcium
angiotensin converting
antagonists may be
enzyme inhibitor or
preferred in isolated
angiotensin receptor blocker
systolic hypertension'

Thiazide like diuretic
(Chlorthalidone,
Indapamide) preferred over
conventional thiazide diuretic
(Bendroflumethiazide,
hydrochlorothiazide)

No evidence to support
RAAS inhibition if older
than 75 years - thiazide-type
diuretic or CCB may be
considered
No evidence based
recommendations for BP
goal in those 70 years or
older with GFR less than
60 mL/min/1.73 m2
'Should be individualised
taking into consideration
factors such as frailty,
comorbidities and albuminuria'

No specific
recommendations

Beta-blockers not preferred initial
therapy for hypertension 'but may
be considered in younger people'
'Offer people aged 80 years and
over the same antihypertensive drug
treatment as people aged 55-80 years,
taking into account any comorbidities'
NICE - National Institute for Health and Clinical Excellence; JNC8 - Eight Joint National Committee; ESH - European Society of
Hypertension; ESC - European Society of Cardiology; SBP - Systolic Blood Pressure, DBP - Diastolic Blood Pressure; ABPM Ambulatory Blood Pressure Monitoring; HBPM - Home Blood Pressure Monitoring; TIA - Transient Ischaemic Attack
4
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of adverse drug reactions, this is recommended for
hypertensive older people.

Pharmacological Therapy
When comparing classes of antihypertensive
agents, none have stood out as superior over others in
terms of cardiovascular outcomes. The International
Verapamil-Trandolapril Study (INVEST) randomised
patients 50 years and over to calcium antagonist
(Verapamil) or non-calcium antagonist strategy
(Atenolol) with trandolapril and hydrochlorothiazide as
required to achieve blood pressure targets. There was
no difference between groups for blood pressure
reduction, myocardial infarction, stroke, mortality or
treatment related adverse events.16
The STOP-Hypertension-2 trial randomised 70
to 84 years old to beta-blockers and diuretics (active
treatment in STOP-Hypertension trial), ACE Inhibitors
or calcium channel blockers.17 All three groups had
similar reductions in systolic blood pressure,
cardiovascular events and rate of treatment related
adverse events. This suggests blood pressure reduction
is more important than type of antihypertensive used.18
However, the three classes with most evidencebase for hypertension treatment of older people are
thiazide-type diuretics, calcium channel blockers and
angiotensin II receptor blockers.

Thiazide-Type Diuretic
The Medical Research Council (MRC) trial
compared outcomes for patients aged 65 to 74 years
randomised to placebo or active treatment with either
atenolol or diuretic (hydrochlorothiazide and amiloride
combined). Active treatment reduced strokes and
cardiovascular events but was more significant with
diuretics.19
Participants aged 60 and older were randomised
to treatment with chlorthalidone and atenolol or placebo
in the Systolic Hypertension in the Elderly Program
(SHEP). Active treatment for almost five years reduced
strokes, major cardiovascular events and all-cause
mortality.20 Non-insulin dependent diabetics also had
twice the absolute risk reduction in major cardiovascular
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events with chlorthalidone compared to non-diabetics
in SHEP.21
The Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT)
reinforced the benefits of thiazide diuretics. Patients
55 years and above were randomised to receive
chlorthalidone, amlodipine or lisinopril. There was no
difference between groups in terms of coronary heart
disease or all-cause mortality. However, amlodipine had
a higher rate of heart failure and lisinopril a higher rate
of combined cardiovascular disease, stroke and heart
failure compared to chlorthalidone.22
The HYVET trial mentioned earlier demonstrated
benefits of indapamide-based diuretic treatment for
hypertensive patients 80 years and over.9 Even with
factoring in frailty using the frailty index, there was no
interaction between treatment effect and frailty, as both
frail and fitter subjects seemed to benefit with treatment.23
At the conclusion of HYVET trial, an open label
active treatment extension was performed for a year,
with both groups given indapamide (and perindopril if
required). The treatment group had reduced
cardiovascular and total mortality but no difference in
stroke and cardiovascular events, suggesting older
patients benefit from early initiation in addition to long
term treatment.24

Calcium-Channel Blockers (CCBs)
The Systolic Hypertension in Europe Trial (SystEur) randomized patients 60 years and older to
nitrendipine (with enalapril and hydrochlorothiazide if
required) or placebo. Treatment was associated with
reduced stroke rates, all cardiac endpoints and all
cardiovascular endpoints with a trend to reduced
cardiovascular mortality.25
This study was replicated in Systolic
Hypertension in China Trial (Syst-China), except
captopril was added instead of enalapril to nitrendipinebased treatment. Despite the smaller sample size, there
were larger-scale benefits with reduced strokes, stroke
mortality, cardiovascular endpoints, cardiovascular
mortality and all-cause mortality.26
As there were concerns regarding CCB treatment
with diabetes, post-hoc analyses were performed
comparing outcomes in diabetic and non-diabetic
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patients. For Syst-Eur, reduction in all cardiovascular
events, cardiovascular mortality and total mortality was
more significant in diabetics.27 In Syst-China, diabetics
had two to three-fold risk for all endpoints in the placebo
group but nitrendipine-based treatment reduced this
excess risk to a non-significant level.28
The Felodipine Event Reduction (FEVER) trial
compared risk of stroke and cardiovascular events
in Chinese patients between 50 to 79 years with
hydrochlorothiazide monotherapy and addition of
felodipine or placebo. Additional felodipine reduced
blood pressure by 4/2 mmHg, with reduced in stroke
rate, cardiovascular events, heart failure and all-cause
mortality.29 Subgroup analysis of FEVER confirmed
benefits of felodipine in uncomplicated hypertensives,
Grade 1 hypertensives and older patients.30 The blood
pressure reduction achieved is unlikely to be clinically
significant to cause such beneficial effects, supporting
use of calcium-channel blockers for older people
regardless of hypertension severity.

Angiotensin II Receptor Blockers (ARBs)
The Valsartan Antihypertensive Long-term Use
Evaluation (VALUE) trial compared cardiac outcomes
in patients age 50 and older randomized to valsartan or
amlodipine. There were larger reductions in blood
pressure especially earlier in the trial with amlodipine
but no differences in myocardial infarction, stroke
and all-cause mortality. 31 In VALUE, additional
antihypertensive agents were added if required. When
analysis was limited to those receiving monotherapy
only, there were lower rates of cardiac failure and newonset diabetes with valsartan.32 The reduction in cardiac
failure with valsartan was more apparent with a longer
duration of monotherapy, suggesting a true treatment
effect.
The Losartan Intervention For Endpoint reduction
in hypertension (LIFE) study compared outcomes in
patients aged 55 to 80 years randomised to losartan or
atenolol-based therapy. Despite no differences in extent
of blood pressure reduction, the losartan group had lower
risk of myocardial infarction, stroke or death and less
frequent episodes of new-onset diabetes.33 This suggests
losartan may confer benefits beyond blood pressure
reduction.
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The Study on Cognition and Prognosis in the
Elderly (SCOPE) reviewed patients aged 70 to 89 years
to candesartan or placebo with open label
antihypertensive agents (mostly thiazides) as required.
Most participants eventually ended up receiving
antihypertensive agents but there was a greater
2.9 mmHg reduction in systolic blood pressure with
candesartan, with associated reduced non-fatal strokes
and a trend towards reduced all strokes. There were no
differences in myocardial infarction, cardiovascular
mortality, cognitive decline or incident dementia.34
When analysis was restricted to those with
isolated systolic hypertension, which was about a third
of the participants, there were no differences in blood
pressure reduction but risk of fatal and non-fatal strokes
became significant.35

Other Agents – Not Recommended as First Line
Therapy for Isolated Systolic Hypertension
ACE Inhibitors (ACEI):
Although ACEIs and ARBs appear to have similar
benefits in younger patients, the evidence for ACEIs is
less clear for older people. The Second Australian
National Blood Pressure Study (ANBP2) randomized
65 to 84 years old to ACEIs or diuretics. Although
enalapril and hydrochlorothiazide were the
recommended agents, actual prescriptions were
determined by the family practitioner. While both groups
had similar reduction in blood pressure, ACEIs were
associated with in reduced cardiovascular events or
death, which was limited to male patients only.36
This contradicts ALLHAT which found diuretics
superior to ACEIs (comparing chlorthalidone to
lisinopril) in terms of cardiac failure and stroke.22 With
this uncertainty, ACEIs should not be used as first-line
hypertension treatment for older people.
Alpha-Blockers:
ALLHAT initially included a doxazosin arm in
addition to chlorthalidone, amlodipine and lisinopril. An
interim analysis four years after recruitment identified
that doxazosin was associated with a higher risk of
stroke, combined cardiovascular risk and doubling of
heart failure risk compared to chlorthalidone. Although
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there were no differences in fatal or non-fatal MI or allcause mortality, due to these identified risks, there were
sufficient grounds to discontinue the doxazosin arm.37
Patients assigned to doxazosin had a higher mean
systolic blood pressure of 3 mmHg than chlorthalidone.
When patients with doxazosin monotherapy or
additional antihypertensive medications were compared,
risk of heart failure was not eliminated completely
suggesting the systolic blood pressure difference does
not account fully for this risk. 38 Therefore, alphaBlockers are not recommended for hypertension
treatment in older people.
Beta-Blockers:
Several studies included beta-blockers in
combination with diuretics so comparisons are not
possible.5,8,21 The LIFE study found losartan superior to
atenolol despite similar blood pressure outcomes.33
While this may be due to beneficial effects of ARBs,
alternatively atenolol could contribute hazardous effects
resulting in this outcome. As there are other preferred
agents for hypertension in older people, beta-blockers
should not be used as first-line treatment.

Conclusion
Ambulatory older people with hypertension
should be treated regardless of age, particularly if
systolic blood pressure is above 160 mmHg. Treatment
should be individualised according to frailty and
comorbidities. Non-pharmacological treatment for
hypertension in older people, including reduced
salt intake and weight loss (if obese) should be
recommended. The main drug classes for hypertension
treatment in older people are thiazide diuretics, calciumchannel blockers and angiotensin II receptor blockers.
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